HIMS
$24.98
Hims & Hers Health, Inc.
Intraday
Recent News
Top 2 S&P 500 Stocks to Watch This Week After Hims & Hers Stock's Surprise Move
These companies are benefiting from a tidal wave of demand for new weight-loss drugs.
Health Care Roundup: Market Talk
1515 ET – For obesity-drug makers, success will be defined by price rather than product differentiation, HSBC analysts say. Pricing competition is set to heat up between Eli Lilly and Novo Nordisk, the analysts say. Lilly’s current guidance — which is more optimistic than Novo Nordisk’s — implies it will get a surge in GLP-1 demand when it cuts prices.
Novo Nordisk Telehealth Deal With Hims And Hers Puts GLP-1 Pricing In Focus
Novo Nordisk (CPSE:NOVO B) has entered a partnership with Hims & Hers to provide access to its FDA approved GLP-1 obesity and diabetes drugs, Ozempic and Wegovy, through telehealth channels. The agreement resolves a public legal dispute between the two companies and could influence how patients in the United States access branded GLP-1 treatments. The announcement comes at a time of increasing competition and the rise of copycat medications in the obesity treatment space. For investors...
Novo Nordisk (NVO) Partners With Hims & Hers, Here’s What You Need to Know
Novo Nordisk A/S (NYSE:NVO) is one of the Most Undervalued Long Term Stocks to Buy According to Analysts. On March 9, Novo Nordisk A/S (NYSE:NVO) announced its partnership with Hims & Hers. The deal entails access to Novo’s GLP-1 drugs, Ozempic and Wegovy, at Hims & Hers’ platform. Management noted that as part of this […]
Hims And Hers Health Pushes Into Complex Care And Global Growth
Hims & Hers Health (NYSE:HIMS) is expanding into complex health categories such as cancer care, longevity treatments, and at-home lab testing. The company is pursuing these areas through acquisitions that aim to bring more of the care journey onto its own platform. Hims & Hers Health is also ramping up international expansion, moving beyond its core US telehealth base. The shift marks a move away from a primary focus on telehealth visits and weight loss drugs toward a broader digital health...